Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

146 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiation Therapy Oncology Group. Research Plan 2002-2006. Gynecology Cancer Working Group.
Greven KM, Levenback C, Chao CK, Delaney T, Del Priore G, Eifel P, Erickson BA, Followill D, Gaffney D, Garcia M, Gerszten K, Grigsby P, Henderson R, Hricak H, Hsu J, Jhingrin A, Kaye A, Kudelka A, Lukka H, Mutch D, Nag S, Rotman M, Shefter T, Smith W, Stehman F, Souhami L, Wenzel L, Winter KA, Wolfson A; Radiation Therapy Oncology Group. Greven KM, et al. Among authors: kudelka a. Int J Radiat Oncol Biol Phys. 2001;51(3 Suppl 2):58-9. Int J Radiat Oncol Biol Phys. 2001. PMID: 11641017 No abstract available.
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix.
Verschraegen CF, Kavanagh JJ, Loyer E, Bodurka-Bevers D, Kudelka AP, Hu W, Vincent M, Nelson T, Levenback C; Community Clinical Oncology Program. Verschraegen CF, et al. Among authors: kudelka ap. Cancer. 2001 Nov 1;92(9):2327-33. doi: 10.1002/1097-0142(20011101)92:9<2327::aid-cncr1579>3.0.co;2-6. Cancer. 2001. PMID: 11745287 Clinical Trial.
A phase II study of intravenous exatecan mesylate (DX-8951f) administered daily for 5 days every 3 weeks to patients with advanced ovarian, tubal or peritoneal cancer resistant to platinum, taxane and topotecan.
Verschraegen CF, Kudelka AP, Hu W, Vincent M, Kavanagh JJ, Loyer E, Bastien L, Duggal A, De Jager R. Verschraegen CF, et al. Among authors: kudelka ap. Cancer Chemother Pharmacol. 2004 Jan;53(1):1-7. doi: 10.1007/s00280-003-0696-7. Epub 2003 Oct 28. Cancer Chemother Pharmacol. 2004. PMID: 14586557 Clinical Trial.
A phase II clinical and pharmacological study of oral 9-nitrocamptothecin in patients with refractory epithelial ovarian, tubal or peritoneal cancer.
Verschraegen CF, Gupta E, Loyer E, Kavanagh JJ, Kudelka AP, Freedman RS, Edwards CL, Harris N, Steger M, Steltz V, Giovanella BC, Stehlin JS. Verschraegen CF, et al. Among authors: kudelka ap. Anticancer Drugs. 1999 Apr;10(4):375-83. doi: 10.1097/00001813-199904000-00005. Anticancer Drugs. 1999. PMID: 10378672 Clinical Trial.
146 results